ArticleEmerging infectious diseases2015
Treatment of Ebola virus infection with antibodies from reconvalescent donors.
Article in Emerging infectious diseases, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed, 25 citations in OpenAlex.
- Monoclonal antibody applications in travel medicine.Tropical diseases, travel medicine and vaccines · 2024Review
- Immunomodulatory nanosystems: An emerging strategy to combat viral infections.Biomaterials and biosystems · 2023Review
- Review
- Adverse effects of Gulf War Illness (GWI) serum on neural cultures and their prevention by healthy serum.Journal of neurology & neuromedicine · 2018Article
- The bulky and the sweet: How neutralizing antibodies and glycan receptors compete for virus binding.Protein science : a publication of the Protein Society · 2017Review
- Anti-Ebola therapies based on monoclonal antibodies: current state and challenges ahead.Critical reviews in biotechnology · 2017Review
- Post-exposure treatment of Ebola virus disease in guinea pigs using EBOTAb, an ovine antibody-based therapeutic.Scientific reports · 2016Article
- Development of a Cost-effective Ovine Polyclonal Antibody-Based Product, EBOTAb, to Treat Ebola Virus Infection.The Journal of infectious diseases · 2016Article
- Dissecting Polyclonal Vaccine-Induced Humoral Immunity against HIV Using Systems Serology.Cell · 2015Article
- Updates on Treatment of Ebola Virus Disease.The Malaysian journal of medical sciences : MJMS · 2015Article
- [Epidemiology of Ebola virus disease and of other highly contagious, life-threatening diseases with low incidence in Germany].Bundesgesundheitsblatt, Gesundheitsforschung, Gesundheitsschutz · 2015Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Clinical evidence suggests that antibodies from reconvalescent donors (persons who have recovered from infection) may be effective in the treatment of Ebola virus infection. Administration of this treatment to Ebola virus-infected patients while preventing the transmission of other pathogenic viruses may be best accomplished by use of virus-inactivated reconvalescent plasma.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.